

6 January 2021

## PYC to present at ICR Westwicke Conference

### Highlights

- PYC has been invited by ICR, a top US investor relations firm, to present at the annual ICR Westwicke Conference on Thursday, January 14, 2021 at 8:30am US Eastern Standard Time
- The ICR conference hosts over 300 public and private companies and is one of the largest investor conferences in the US
- PYC's management will also hold virtual investor meetings at the conference

### Announcement

PYC Therapeutics, (ASX:PYC) ('PYC' or 'the Company') is pleased to announce the Company's participation in the 2021 ICR Westwicke Conference being held on the on January 12-14. The Company's US Chief Executive Officer, Sahm Nasser, will be presenting on Thursday January 14 at 8:30am US Eastern Standard Time.

A live webcast will be available at the following link and a recording will be posted to the Investor Section of PYC's website (pyctx.com) for 90 days.

**Date & Time:** Thursday, January 14, 2021 at 8:30am EST

**Webcast Link:** <https://icrinc.touchcast.com/showtime/icr-conference/embed/a5caa3c3-1dd6-acc7-31d9-a362862d1391>

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

**ENDS**

For further information, please contact:

#### INVESTORS

Kaggen Ausma  
CBO  
info@pyctx.com

## **About PYC Therapeutics**

*PYC Therapeutics (ASX: PYC) is a drug development company based in the United States and Australia, progressing life-changing science towards areas of important unmet patient need.*

*The Company combines world-leading RNA therapeutics design with a revolutionary delivery technology based on Cell Penetrating Peptides (CPPs) to overcome the major challenges of current gene-therapies. PYC's CPPs solve the 'delivery challenge', providing safe and effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which PYC has 3 defined pre-clinical programs.*

## **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

pyctx.com

**PYC Therapeutics Limited**

ACN 098 391 961